Galderma Group

Aging Global Demand And Minimally Invasive Procedures Will Reinvent Aesthetics

AnalystHighTarget

Not Invested

Consensus Narrative from 12 Analysts

Published

30 Aug 25

AnalystHighTarget's Fair Value

CHF 164.34

12.0% undervalued

05 Sep

CHF 144.70

82.1%

3.7%

82.1%

3.7%

Edit anytime before Aug 30 9:22 PM. Then post Updates to your followers.

Author's Valuation

CHF 164.3

12.0% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

CHF 164.3

12.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

13.07%

Pharma revenue growth rate

0.59%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

3.82%

Calculation

US$1.64b

Earnings '28

32.66x

PE Ratio '28

US$53.64b

Market Cap '28

US$53.64b

Market Cap '28

235.14m

No. shares '28

US$228.12

Share Price '28

US$228.12 Share Price '28

Discounted to 2025 @ 3.82% p.a.

US$203.87

Fair Value '25

US$203.87 Fair Value '25

Converted to CHF @ 0.8056 USD/CHF Exchange Rate

CHF 164.25

Fair Value '25